Intermittent Hypoxia Triggers Early Cardiac Remodeling and Contractile Dysfunction in the Time-Course of Ischemic Cardiomyopathy in Rats.
Animals
Blood Pressure
/ physiology
Cardiomyopathies
/ complications
Disease Models, Animal
Disease Progression
Endoplasmic Reticulum Stress
/ physiology
Heart
Hypoxia
/ complications
Hypoxia-Inducible Factor 1
/ metabolism
Lung
/ pathology
Male
Myocardial Contraction
/ physiology
Myocardial Infarction
/ pathology
Myocardial Ischemia
/ etiology
Myocardium
/ pathology
Rats
Rats, Wistar
Sleep Apnea Syndromes
/ complications
Time Factors
Ventricular Remodeling
/ physiology
ER stress
hypoxia inducible factor‐1
intermittent hypoxia
ischemic cardiomyopathy
sleep‐disordered breathing
sympathetic activation
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
18 08 2020
18 08 2020
Historique:
pubmed:
18
8
2020
medline:
10
3
2021
entrez:
18
8
2020
Statut:
ppublish
Résumé
BACKGROUND Sleep-disordered breathing is associated with a poor prognosis (mortality) in patients with ischemic cardiomyopathy. The understanding of mechanisms linking intermittent hypoxia (IH), the key feature of sleep-disordered breathing, to ischemic cardiomyopathy progression is crucial for identifying specific actionable therapeutic targets. The aims of the present study were (1) to evaluate the impact of IH on the time course evolution of cardiac remodeling and contractile dysfunction in a rat model of ischemic cardiomyopathy; and (2) to determine the impact of IH on sympathetic activity, hypoxia inducible factor-1 activation, and endoplasmic reticulum stress in the time course of ischemic cardiomyopathy progression. METHODS AND RESULTS Ischemic cardiomyopathy was induced by a permanent ligature of the left coronary artery in male Wistar rats (rats with myocardial infarction). Rats with myocardial infarction were then exposed to either IH or normoxia for up to 12 weeks. Cardiac remodeling and function were analyzed by Sirius red and wheat germ agglutinin staining, ultrasonography, and cardiac catheterization. Sympathetic activity was evaluated by spectral analysis of blood pressure variability. Hypoxia-inducible factor-1α activation and burden of endoplasmic reticulum stress were characterized by Western blots. Long-term IH exposure precipitated cardiac remodeling (hypertrophy and interstitial fibrosis) and contractile dysfunction during the time course evolution of ischemic cardiomyopathy in rodents. Among associated mechanisms, we identified the early occurrence and persistence of sympathetic activation, associated with sustained hypoxia-inducible factor-1α expression and a delayed pro-apoptotic endoplasmic reticulum stress. CONCLUSIONS Our data provide the demonstration of the deleterious impact of IH on post-myocardial infarction remodeling and contractile dysfunction. Further studies are needed to evaluate whether targeting sympathetic nervous system or HIF-1 overactivities could limit these effects and improve management of coexisting ischemic cardiomyopathy and sleep-disordered breathing.
Identifiants
pubmed: 32805159
doi: 10.1161/JAHA.120.016369
pmc: PMC7660805
doi:
Substances chimiques
Hypoxia-Inducible Factor 1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e016369Références
Cardiovasc Res. 2011 Aug 1;91(3):447-55
pubmed: 21493701
Sleep. 2013 Apr 01;36(4):481-92
pubmed: 23564995
Eur Heart J. 2014 Jan;35(3):192-9
pubmed: 24164862
J Appl Physiol (1985). 2009 Sep;107(3):787-93
pubmed: 19589954
Eur Respir Rev. 2019 Jul 31;28(153):
pubmed: 31366458
PLoS One. 2014 Apr 09;9(4):e94545
pubmed: 24718591
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Nat Rev Dis Primers. 2015 Jun 25;1:15015
pubmed: 27188535
Int J Cardiol. 2016 May 1;210:45-53
pubmed: 26922713
Nat Commun. 2017 Jul 25;8(1):133
pubmed: 28743963
Am J Respir Crit Care Med. 2011 Sep 15;184(6):724-31
pubmed: 21680945
J Appl Physiol (1985). 2006 Jun;100(6):1974-82
pubmed: 16484362
Circulation. 1994 Jan;89(1):345-54
pubmed: 8281668
Cardiovasc Res. 2012 Apr 1;94(1):77-86
pubmed: 22258630
ILAR J. 2009;50(3):262-81
pubmed: 19506313
Sci Rep. 2018 Feb 14;8(1):2997
pubmed: 29445096
Plant Mol Biol. 2012 Jan 31;:
pubmed: 22290409
PLoS One. 2010 Jul 21;5(7):e11693
pubmed: 20657781
Circulation. 2012 Oct 16;126(16):2020-35
pubmed: 22923432
Apoptosis. 2013 Jul;18(7):800-10
pubmed: 23620435
Circulation. 2008 Nov 11;118(20):2057-62
pubmed: 18955667
Heart Fail Rev. 2009 Dec;14(4):225-41
pubmed: 19110970
Sci Rep. 2018 Dec 18;8(1):17939
pubmed: 30560874
J Am Coll Cardiol. 2009 Apr 14;53(15):1309-17
pubmed: 19358946
Annu Rev Physiol. 2013;75:49-67
pubmed: 23020580
Lancet Respir Med. 2020 Apr;8(4):323-325
pubmed: 31839559
Eur Respir J. 2015 Feb;45(2):419-27
pubmed: 25573410
J Am Heart Assoc. 2020 Aug 18;9(16):e016369
pubmed: 32805159
J Appl Physiol (1985). 2007 May;102(5):1806-14
pubmed: 17272404
BMC Cardiovasc Disord. 2015 Jul 30;15:79
pubmed: 26223692
Eur Heart J. 2015 Jun 14;36(23):1463-9
pubmed: 25636743
Circulation. 2010 Jul 27;122(4):361-9
pubmed: 20625112
JCI Insight. 2016 Dec 22;1(21):e90240
pubmed: 28018974
Circulation. 2010 Jul 27;122(4):352-60
pubmed: 20625114
Toxicol Lett. 2014 Jun 5;227(2):113-23
pubmed: 24680926
Mol Cell Biochem. 2012 May;364(1-2):59-70
pubmed: 22270541
Lancet Respir Med. 2020 Apr;8(4):359-367
pubmed: 31839558
Int J Cardiol. 2014 Sep;176(1):13-9
pubmed: 25064202
N Engl J Med. 2016 Sep 8;375(10):919-31
pubmed: 27571048
J Physiol. 2006 Dec 1;577(Pt 2):705-16
pubmed: 16973705
Am J Physiol Heart Circ Physiol. 2001 Jun;280(6):H2902-10
pubmed: 11356651
Am J Physiol Heart Circ Physiol. 2016 Jan 15;310(2):H279-89
pubmed: 26566725
Pharmacol Ther. 2016 Dec;168:1-11
pubmed: 27492897
Ther Adv Chronic Dis. 2020 Jun 24;11:2040622320922104
pubmed: 32637058